Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAS-004 in Adult Participants With Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas
NCT06961565Phase 1Recruiting
- Sponsor
- Pasithea Therapeutics
- Start
- May 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pas-004 in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) (3 arms), sponsored by Pasithea Therapeutics. Primary endpoint: Safety and tolerability of PAS-004 at 28 days. Started May 2025; status: recruiting.
02
Drugs
pas-004
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT06961565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961565.